

NATH SEEDS®

## **Nath Bio-Genes (I) Ltd.**

(CIN L01110MH1993PLC072842)

11<sup>th</sup> February 2022

The Manager-Listing  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

The Manager-Listing  
National Stock Exchange of India Ltd.,  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E)  
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on 11<sup>th</sup> February 2022, has approved the standalone unaudited financial results, for the quarter and nine months ended 31<sup>st</sup> December, 2021.

Pursuant to above-referred regulations, we enclose the following documents.

1. Statement of unaudited financial results, (Standalone) for the quarter and nine months ended 31<sup>st</sup> December 2021. (Annexure-I)
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II).

The Meeting Commenced on 02:30 p.m. and Concluded on 04:00 p.m.

The above information will be made available on the Company's website [www.nathbiogenes.com](http://www.nathbiogenes.com).

You are requested to take the above information on record.

Thanking You

Yours faithfully,  
For Nath Bio-Genes (India) Limited

Devinder Khurana  
Chief Financial Officer

**Nath Bio-Genes (I) Ltd.**

CIN: L01104M-1903PLC072542

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31/12/2021**

Rs in Lacs

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31/12/2021 Unaudited	30/09/2021 Unaudited	31/12/2020 Unaudited	31/12/2021 Unaudited	31/12/2020 Unaudited	31/03/2021 Audited
I	<b>Income</b>						
	(a) Revenue from operations	2165.78	1485.69	3603.08	25115.05	25254.54	30756.11
	(b) Other Operating Income	28.18	38.00	92.79	112.89	177.49	166.95
	<b>Total Income</b>	<b>2193.96</b>	<b>1523.69</b>	<b>3695.86</b>	<b>25227.94</b>	<b>25432.03</b>	<b>30923.06</b>
II	<b>Expenses</b>						
	a) Production Expenses	2526.25	518.05	2620.35	13016.75	10332.17	14890.00
	b) Purchase of Stock-in-Trade	129.16	245.89	73.36	424.88	538.53	895.50
	c) Change in Inventories of Produced and Traded Goods	(1934.43)	(524.06)	(1553.65)	(1800.38)	339.36	(2176.20)
	d) Employee Benefit Expense	480.72	495.15	493.97	1718.46	1400.95	2368.86
	e) Finance Costs	270.40	278.09	209.91	814.22	608.87	881.94
	f) Depreciation & Amortisation Expenses	67.73	67.87	67.24	203.33	201.06	281.59
	g) Selling & Distribution Expenses	112.83	140.24	716.54	4463.43	5306.21	5839.10
	h) Admin & R&D Expenditure	250.53	168.45	614.16	1442.84	1779.22	2267.16
	<b>Total Expenses</b>	<b>1903.19</b>	<b>1389.67</b>	<b>3241.88</b>	<b>20283.52</b>	<b>20506.38</b>	<b>25247.95</b>
III	Profit before Exceptional Items & Tax (I - II)	290.77	134.01	453.98	4944.42	4925.65	5675.11
IV	Exceptional Items Income/(Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
V	<b>Profit Before Tax (III+IV)</b>	<b>290.77</b>	<b>134.01</b>	<b>453.98</b>	<b>4944.42</b>	<b>4925.65</b>	<b>5675.11</b>
VI	<b>Tax Expense</b>						
	(a) Current Tax	10.03	10.95	29.24	49.45	73.78	0.00
	(b) Earlier Year Tax	0.00	0.00	0.00	0.00	0.00	39.58
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	69.37
VII	<b>Net Profit for the period (V-VI)</b>	<b>280.75</b>	<b>123.06</b>	<b>424.74</b>	<b>4894.97</b>	<b>4851.87</b>	<b>5566.16</b>
VIII	<b>Other Comprehensive Income</b>						
	1 (a) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2 (a) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total other Comprehensive Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
IX	<b>Total Comprehensive Income for the period (VII + VIII)</b>	<b>280.75</b>	<b>123.06</b>	<b>424.74</b>	<b>4894.97</b>	<b>4851.87</b>	<b>5566.16</b>
X	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XI	Reserve & Surplus	64322.45	63661.62	58713.19	64322.45	58713.19	59427.48
XII	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	1.48	0.65	2.23	25.76	25.53	29.29

**NOTES:**

(1) The financial results were reviewed by the Audit Committee in meeting held on 11 February 2022 and were thereafter approved by the Board of Directors at its meeting held on 11 February 2022.

(2) The company is dealing in one major product segment, i.e. Seed Cultivation.

(3) The figures have been regrouped/rearranged where ever necessary.

FOR NATH BIO-GENES (INDIA) LTD

Satish Kaglwal  
MANAGING DIRECTOR  
DIN 00119601

Place : Aurangabad

Date : 11 February 2022

Regd. Office : Nath House, Nath Road, Aurangabad - 431005 (MS)  
www.nathbiogenes.com



ASHOK R. MAJETHIA

BCom. F.C.A  
CHARTERED ACCOUNTANT

Ashok R. Majethia & Co.  
Chartered Accountants  
Utsav Complex,  
Office No. 7, Bazar Peth,  
Dist. Raigad, Khopoli – 410 203  
Tel :- (02192) 269908  
Mobile :- 9404711539 / 9372169952  
Email :- ashokmajethia@redifmail.com

## LIMITED REVIEW REPORT


To,  
The Board of Directors,  
Nath Bio-Genes (India) Limited  
Aurangabad

1. We have reviewed the accompanying statement of unaudited financial results of Nath Bio-Genes (India) Limited for the quarter ended 31<sup>st</sup> December 2021 and year to date results for the period 1<sup>st</sup> April 2021 to 31<sup>st</sup> December 2021 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ashok R Majethia & Co.  
Chartered Accountants  
(Registration No. 127769W)



Ashok R. Majethia  
Proprietor  
M No: 124781



UDIN: 22124781ABHYBM1526

Place: Khopoli Dist Raigad  
Date: 11<sup>th</sup> February 2022